<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591422</url>
  </required_header>
  <id_info>
    <org_study_id>SGC1001</org_study_id>
    <nct_id>NCT00591422</nct_id>
  </id_info>
  <brief_title>Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas</brief_title>
  <official_title>Phase I Study of Oral Darinaparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziopharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziopharm</source>
  <brief_summary>
    <textblock>
      The study of Dariniparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicities</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZIO-101-C (Darinaparsin)</intervention_name>
    <description>Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (&gt;36 hours between doses) for 3 weeks with 1 week rest.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>ZIO-101-C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Patients with non-Hodgkin's Lymphomas that are refractory to standard therapies for&#xD;
             their condition.(As of protocol amendment 6.0 dated 8/26/2009)&#xD;
&#xD;
          2. Men and women of ≥ 18 years of age.&#xD;
&#xD;
          3. ECOG performance score ≤ 2 (see Appendix 4).&#xD;
&#xD;
          4. Eligible subjects with lymphomas must have measurable disease as defined by the&#xD;
             revised International Working Group response criteria (Appendix 7)&#xD;
&#xD;
          5. Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          6. Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             requirements, to be conducted &lt;2 weeks prior to Baseline:&#xD;
&#xD;
               -  Creatinine ≤ 2X upper limit of normal (ULN) OR a calculated creatinine clearance&#xD;
                  ≥ 50 cc/min&#xD;
&#xD;
               -  Total bilirubin ≤ 2X ULN&#xD;
&#xD;
               -  Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 3X ULN&#xD;
&#xD;
               -  Granulocytes in peripheral blood ≥1 x 109/L, hemoglobin ≥8.5 g/dL, and platelets&#xD;
                  ≥50,000 /µL&#xD;
&#xD;
          7. Written informed consent in compliance with ZIOPHARM policies and the Human&#xD;
             Investigation Review Committee (IEC/IRB) having jurisdiction over the site.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. New York Heart Association (NYHA) functional class ≥3 myocardial infarction (see&#xD;
             Appendix 5) within 6 months.&#xD;
&#xD;
          2. Uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation; a QTc&#xD;
             ≥450 msec; or a ≥Grade 2 atrioventricular (AV) block or left bundle branch block&#xD;
             (LBBB); or documented history of prolonged QTc.&#xD;
&#xD;
          3. Pregnant and/or lactating female. (Women of childbearing age must use effective&#xD;
             contraception from Screening through the duration of Study participation.)&#xD;
&#xD;
          4. Uncontrolled systemic infection (documented with microbiological studies).&#xD;
&#xD;
          5. Metastatic brain or meningeal tumors.&#xD;
&#xD;
          6. Patients with seizure disorder requiring medication (such as anti-epileptics).&#xD;
&#xD;
          7. History of confusion or dementia or neurological condition that could mask a potential&#xD;
             adverse response to Study Drug which may include transient ischemic attack,&#xD;
             Parkinson's disease, thrombotic or hemorrhagic stroke, Alzheimers, and other&#xD;
             neurological disorders.&#xD;
&#xD;
          8. Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of Study&#xD;
             entry (mitomycin C or nitrosureas should not be given within 6 weeks of Study entry).&#xD;
&#xD;
          9. Radiotherapy during study or within 3 weeks of Study entry.&#xD;
&#xD;
         10. Surgery within 4 weeks of start of Study Drug.&#xD;
&#xD;
         11. Investigational drug therapy outside of this trial during or within 4 weeks of Study&#xD;
             entry.&#xD;
&#xD;
         12. History of invasive second primary malignancy diagnosed within the previous 3 years&#xD;
             except for Stage I endometrial/cervical carcinoma or prostate carcinoma treated&#xD;
             surgically, and non-melanoma skin cancer.&#xD;
&#xD;
         13. Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of Study results.&#xD;
&#xD;
         14. Any condition that is unstable or could jeopardize the safety of the patient and&#xD;
             his/her compliance in the Study.&#xD;
&#xD;
         15. Arsenic allergy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Lewis, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ziopharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>July 18, 2012</last_update_submitted>
  <last_update_submitted_qc>July 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arsenic</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

